Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UGT2B25P is a member of the UDP glucuronosyltransferase family but is a pseudogene, meaning it does not encode a functional protein and lacks catalytic activity. It is not considered a therapeutic target, and there are no known disease, functional roles, or drug interactions associated with this locus[1]. A *pseudogene* is a segment of DNA resembling a gene but is nonfunctional due to mutations or lack of regulatory elements. UGT2B25P is located within a cluster of similar genes and pseudogenes on chromosome 4, paralleling functional UGT family members such as UGT2B7 and UGT2B15, which are active phase II metabolism enzymes[2][3][4][5][6]. However, UGT2B25P itself does not encode any known functional protein, molecular pathway, or therapeutic relevance[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on UDP glucuronosyltransferase family 2 member B25, pseudogene (UGT2B25P).